Results 201 to 210 of about 181,705 (382)

Simultaneous T1, T2, and T1ρ mapping of the myocardium using cardiac MR fingerprinting with a deep image prior reconstruction

open access: yesMagnetic Resonance in Medicine, EarlyView.
Abstract Purpose To develop a cardiac MR fingerprinting (cMRF) approach using deep image prior reconstruction (DIP) to simultaneously map T1, T2, and T1ρ, and assess T1ρ in healthy subjects and patients with areas of enhancement on late gadolinium enhancement.
Sydney Kaplan   +6 more
wiley   +1 more source

Peripheral Nervous System Involvement of Hereditary Transthyretin Amyloidosis in the United States: A Multi‐Center Perspective

open access: yesMuscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Hereditary transthyretin amyloidosis (ATTRv) is an autosomal dominant multisystem disorder that occurs worldwide. The most common mutation in the United States, V142I, has previously been described as having a primarily cardiac presentation.
Urvi Desai   +3 more
wiley   +1 more source

A new staging system for cardiac transthyretin amyloidosis

open access: yesEuropean Heart Journal, 2018
J. Gillmore   +14 more
semanticscholar   +1 more source

A functional role for spontaneously occurring natural anti‐transthyretin antibodies from patients with transthyretin cardiac amyloidosis

open access: yes
European Journal of Heart Failure, EarlyView.
Ortal Tuvali   +5 more
wiley   +1 more source

Investigating Local Sequence‐Structural Attributes of Amyloidogenic Light Chain Variable Domains

open access: yesProteins: Structure, Function, and Bioinformatics, EarlyView.
ABSTRACT Light chain amyloidosis is a medical condition characterized by the aggregation of misfolded antibody light chains into insoluble amyloid fibrils in the target organs, causing organ dysfunction, organ failure, and death. Despite extensive research to understand the factors contributing to amyloidogenesis, accurately predicting whether a given ...
Puneet Rawat   +6 more
wiley   +1 more source

Nanoparticle Therapeutics in Clinical Perspective: Classification, Marketed Products, and Regulatory Landscape

open access: yesSmall, EarlyView.
This review presents a detailed overview of clinically approved nanoparticle therapeutics, classifying them by type and discussing their unique advantages in drug delivery. It highlights regulatory challenges across global markets and emphasizes the need for adaptive approval pathways.
Nimeet Desai   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy